Get the Stockscreener App
12.85
3.69%
0.3932
Indivior Plc stock is traded at $12.85, with a volume of 361.08K.
It is up +3.69% in the last 24 hours and up +7.85% over the past month.
Indivior PLC is a specialty and generic drug manufacturing company. The company is focused on the development, manufacture, and sale of prescription drugs for treatment of substance use disorders and other serious mental illnesses. Its products include, Sublocade, Perseris, Suboxone, Opvee among others. The vast majority of Indivior's revenue is generated in the United States, followed by United Kingdom and the rest of the world.
See More
Previous Close:
$12.46
Open:
$12.38
24h Volume:
361.08K
Relative Volume:
0.34
Market Cap:
$1.61B
Revenue:
$1.12B
Net Income/Loss:
$5.00M
P/E Ratio:
1,285.32
EPS:
0.01
Net Cash Flow:
$-383.00M
1W Performance:
+9.26%
1M Performance:
+7.85%
6M Performance:
+15.36%
1Y Performance:
-29.63%
1-Day Range:
$12.36
$12.94
1-Week Range:
$11.83
$12.98
52-Week Range:
$7.33
$18.50
Indivior Plc Stock (INDV) Company Profile
Name
Indivior Plc
Sector
Phone
804-379-1090
Address
234 BATH ROAD, SLOUGH, BERKSHIRE
Compare INDV with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INDV
Indivior Plc
|
12.91 | 1.48B | 1.12B | 5.00M | -383.00M | 0.01 |
|
HLN
Haleon Plc Adr
|
11.17 | 50.54B | 14.35B | 1.85B | 0 | 0.4023 |
|
ZTS
Zoetis Inc
|
170.98 | 74.02B | 9.29B | 2.52B | 2.28B | 5.57 |
|
RDHL
Redhill Biopharma Ltd Adr
|
1.8368 | 4.22M | 35.75M | 11.57M | -26.25M | -3.8069 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.95 | 45.82B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
17.18 | 20.31B | 16.54B | -1.64B | 749.00M | -1.45 |
Indivior Plc Stock (INDV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-28-25 | Initiated | Rodman & Renshaw | Buy |
| Jul-23-24 | Initiated | Piper Sandler | Overweight |
| Apr-03-24 | Initiated | Craig Hallum | Buy |
| Jul-13-23 | Initiated | Northland Capital | Outperform |
Indivior Plc Stock (INDV) Latest News
Opioid Use Disorder Market Projected to Witness Massive GrowthIndivior PLC, Alkermes plc - openPR.com
Trending tickers: The latest investor updates on Tesla, Palantir, Sanofi, Babcock and Indivior - Yahoo
Kalkine : Indivior’s Exit from London Exchange Impacts FTSE 100 Pharmaceutical Landscape - Kalkine Media
Indivior to delist from London Stock Exchangewill stay on Nasdaq - Insider Media Ltd
Drug maker Indivior joins London Stock Exchange exodus, 2 Jun 2025 11:00 - Shares Magazine
Kalkine : Indivior’s FTSE 100 Sector Shift: Delisting from London to Focus on Nasdaq Listing - Kalkine Media
Kalkine: Indivior Exits London as FTSE 100 Firm Focuses on Nasdaq - Kalkine Media
FTSE pharma giant joins London stock market exodus - The Telegraph
Indivior (INDV) Delists from London to Focus on U.S. Market - GuruFocus
Indivior to delist from London Stock Exchange, maintain primary listing on Nasdaq - MSN
Indivior brings curtain down on turbulent 11-year run in London - Proactive financial news
Indivior drops London listing to focus on U.S. market By Investing.com - Investing.com Nigeria
Indivior To Delist From LSE To Better Align With US Focused Business - Nasdaq
Indivior to cancel secondary listing in London - Sharecast.com
Indivior Plans to Cancel London Listing After Moving Primary to US - Bloomberg
Drug maker Indivior to abandon London stock market for the US - Yahoo
Indivior to Cancel London Stock Exchange Listing, Focuses on Nasdaq - TipRanks
Indivior to Cancel Secondary Listing on London Stock Exchange, Maintains Primary Nasdaq Listing | Indivior Stock News - paginasiete.bo
Indivior to delist from London Stock Exchange, maintain Nasdaq listing - marketscreener.com
Indivior Announces Intention to Cancel Secondary Listing on London Stock Exchange; Primary Listing on Nasdaq to be Maintained | INDV Stock News - GuruFocus
Indivior Announces Intention to Cancel Secondary Listing on London Stock Exchange; Primary Listing on Nasdaq to be Maintained - Bluefield Daily Telegraph
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of October 1, 2024 in Indivior PLC LawsuitINDV - ACCESS Newswire
Indivior Announces Patrick Barry as Chief Commercial Officer - The Malaysian Reserve
Indivior appoints Patrick Barry as Chief Commercial Officer By Investing.com - Investing.com South Africa
Indivior Announces Patrick Barry as Chief Commercial Officer | I - GuruFocus
Indivior Announces Patrick Barry as Chief Commercial Officer | INDV Stock News - GuruFocus
Indivior Taps Former Endo Executive to Drive SUBLOCADE Growth Strategy - Stock Titan
Indivior PLC (INDV) Stock Analysis: A 30% Upside Potential Amidst Strong Buy Ratings - DirectorsTalk Interviews
Investors in Indivior (LON:INDV) have seen solid returns of 156% over the past five years - Yahoo Finance
How To Trade (INDV) - news.stocktradersdaily.com
Indivior PLC (LON:INDV) Held Back By Insufficient Growth Even After Shares Climb 26% - simplywall.st
Naloxone Market Projected To Witness Massive Growth, 2025-2032 - openPR.com
Court of Appeal upholds representative action strike out in Wirral Council v Indivior/Reckitt, but claimant applies for permission to appeal to Supreme Court - stewartslaw.com
Indivior PLC Aligns CEO Compensation with Long-Term Performance Goals - TipRanks
Indivior to Participate in Upcoming Investor Events - StreetInsider
Indivior to Participate in Upcoming Investor Events | INDV Stock News - GuruFocus
Indivior announces participation in investor conferences By Investing.com - Investing.com India
Indivior to Engage with Investors at Key Healthcare Conferences - TipRanks
Indivior to Participate in Upcoming Investor Events – Company Announcement - Financial Times
Drug Addiction Treatment Market Projected To Witness Massive - openPR.com
(INDV) Long Term Investment Analysis - news.stocktradersdaily.com
Drug Abuse Treatment Market Grows Amid Rising Substance Abuse - openPR.com
Indivior advances GABA-B PAM program for substance use disorders through IND-enabling studies - BioWorld MedTech
Addex Partner Indivior Advances GABAB Positive Allosteric Modulator Program Successfully Through IND Enabling Studies - Yahoo
Shareholders of Indivior PLC Should Contact Levi & Korsinsky Before October 1, 2024 to Discuss Your RightsINDV - ACCESS Newswire
Levi & Korsinsky Investigates Possible Securities Fraud Violations by Indivior PLC (INDV) - ACCESS Newswire
Indivior PLC Announces AGM Results with Key Resolutions Passed - TipRanks
Indivior PLC Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky for More InformationINDV - ACCESS Newswire
Indivior PLC Sued for Securities Law ViolationsContact Levi & Korsinsky Before October 1, 2024 to Discuss Your Rights – INDV - ACCESS Newswire
Indivior Plc Stock (INDV) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.28%
2.99%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):